Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations

The majority of Mycobacterium tuberculosis isolates resistant to isoniazid harbour a mutation in katG . Since these mutations cause a wide range of minimum inhibitory concentrations (MICs), largely below the serum level reached with higher dosing (15 mg/L upon 15–20 mg/kg), the drug might still rema...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2018-02, Vol.8 (1), p.3246-9, Article 3246
Hauptverfasser: Lempens, Pauline, Meehan, Conor J., Vandelannoote, Koen, Fissette, Kristina, de Rijk, Pim, Van Deun, Armand, Rigouts, Leen, de Jong, Bouke C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 9
container_issue 1
container_start_page 3246
container_title Scientific reports
container_volume 8
creator Lempens, Pauline
Meehan, Conor J.
Vandelannoote, Koen
Fissette, Kristina
de Rijk, Pim
Van Deun, Armand
Rigouts, Leen
de Jong, Bouke C.
description The majority of Mycobacterium tuberculosis isolates resistant to isoniazid harbour a mutation in katG . Since these mutations cause a wide range of minimum inhibitory concentrations (MICs), largely below the serum level reached with higher dosing (15 mg/L upon 15–20 mg/kg), the drug might still remain partly active in presence of a katG mutation. We therefore investigated which genetic mutations predict the level of phenotypic isoniazid resistance in clinical M. tuberculosis isolates. To this end, the association between known and unknown isoniazid resistance-conferring mutations in whole genome sequences, and the isoniazid MICs of 176 isolates was examined. We found mostly moderate-level resistance characterized by a mode of 6.4 mg/L for the very common katG Ser315Thr mutation, and always very high MICs (≥19.2 mg/L) for the combination of katG Ser315Thr and inhA c-15t. Contrary to common belief, isolates harbouring inhA c-15t alone, partly also showed moderate-level resistance, particularly when combined with inhA Ser94Ala. No overt association between low-confidence or unknown mutations, except in katG , and isoniazid resistance (level) was found. Except for the rare katG deletion, line probe assay is thus not sufficiently accurate to predict the level of isoniazid resistance for a single mutation in katG or inhA .
doi_str_mv 10.1038/s41598-018-21378-x
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5818527</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2004118262</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-e5b4443e3e1960c190480bfc9b67bfac5f676b54f0e0df84815cd1089fdc4e073</originalsourceid><addsrcrecordid>eNp9kcFuFSEUhidGY5vaF3BhSNy4GQUGZmBjYpqqTWrc6JoAc7iXhoErzDS97n1vmd7aVheyOQQ-Pjj8TfOS4LcEd-JdYYRL0WIiWkq6QbQ3T5pjihlvaUfp00fzo-a0lCtcB6eSEfm8OaqVy76Xx82vi5Ki1z_9iDIUX2YdLaAA1xAKSg592dtktJ0h-2VC82Ig2yWkSiKrIwo6byDskQG0yzD6Co7I7NHWb7atTdH5EVbhg_t2FXL2cYOmZdazT7G8aJ45HQqc3tWT5vvH829nn9vLr58uzj5ctpYTMrfADWOsgw6I7LElEjOBjbPS9INx2nLXD73hzGHAoxNMEG5HgoV0o2WAh-6keX_w7hYzwWghzlkHtct-0nmvkvbq753ot2qTrhUXRHC6Ct7cCXL6sUCZ1eSLhRB0hLQURTEeCOkHIiv6-h_0Ki051vZWihEiaE8rRQ-UzamUDO7-MQSrNWh1CFrVoNVt0OqmHnr1uI37I39irUB3AMpu_WjID3f_R_sbz824mQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2004118262</pqid></control><display><type>article</type><title>Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA Free Journals</source><source>Nature Free</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Lempens, Pauline ; Meehan, Conor J. ; Vandelannoote, Koen ; Fissette, Kristina ; de Rijk, Pim ; Van Deun, Armand ; Rigouts, Leen ; de Jong, Bouke C.</creator><creatorcontrib>Lempens, Pauline ; Meehan, Conor J. ; Vandelannoote, Koen ; Fissette, Kristina ; de Rijk, Pim ; Van Deun, Armand ; Rigouts, Leen ; de Jong, Bouke C.</creatorcontrib><description>The majority of Mycobacterium tuberculosis isolates resistant to isoniazid harbour a mutation in katG . Since these mutations cause a wide range of minimum inhibitory concentrations (MICs), largely below the serum level reached with higher dosing (15 mg/L upon 15–20 mg/kg), the drug might still remain partly active in presence of a katG mutation. We therefore investigated which genetic mutations predict the level of phenotypic isoniazid resistance in clinical M. tuberculosis isolates. To this end, the association between known and unknown isoniazid resistance-conferring mutations in whole genome sequences, and the isoniazid MICs of 176 isolates was examined. We found mostly moderate-level resistance characterized by a mode of 6.4 mg/L for the very common katG Ser315Thr mutation, and always very high MICs (≥19.2 mg/L) for the combination of katG Ser315Thr and inhA c-15t. Contrary to common belief, isolates harbouring inhA c-15t alone, partly also showed moderate-level resistance, particularly when combined with inhA Ser94Ala. No overt association between low-confidence or unknown mutations, except in katG , and isoniazid resistance (level) was found. Except for the rare katG deletion, line probe assay is thus not sufficiently accurate to predict the level of isoniazid resistance for a single mutation in katG or inhA .</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-018-21378-x</identifier><identifier>PMID: 29459669</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>45/22 ; 45/23 ; 631/208/205 ; 631/326/22/1434 ; 631/326/2521 ; 631/326/41/2530 ; 631/326/421 ; Antitubercular Agents - pharmacology ; Bacterial Proteins - genetics ; Catalase - genetics ; Drug Resistance, Bacterial ; Genomes ; Humanities and Social Sciences ; Humans ; Isoniazid ; Isoniazid - pharmacology ; Microbial Sensitivity Tests ; multidisciplinary ; Mutation ; Mycobacterium tuberculosis ; Mycobacterium tuberculosis - drug effects ; Mycobacterium tuberculosis - genetics ; Mycobacterium tuberculosis - isolation &amp; purification ; Oxidoreductases - genetics ; Science ; Science (multidisciplinary) ; Tuberculosis ; Tuberculosis - microbiology</subject><ispartof>Scientific reports, 2018-02, Vol.8 (1), p.3246-9, Article 3246</ispartof><rights>The Author(s) 2018</rights><rights>2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-e5b4443e3e1960c190480bfc9b67bfac5f676b54f0e0df84815cd1089fdc4e073</citedby><cites>FETCH-LOGICAL-c511t-e5b4443e3e1960c190480bfc9b67bfac5f676b54f0e0df84815cd1089fdc4e073</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818527/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818527/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,27928,27929,41124,42193,51580,53795,53797</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29459669$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lempens, Pauline</creatorcontrib><creatorcontrib>Meehan, Conor J.</creatorcontrib><creatorcontrib>Vandelannoote, Koen</creatorcontrib><creatorcontrib>Fissette, Kristina</creatorcontrib><creatorcontrib>de Rijk, Pim</creatorcontrib><creatorcontrib>Van Deun, Armand</creatorcontrib><creatorcontrib>Rigouts, Leen</creatorcontrib><creatorcontrib>de Jong, Bouke C.</creatorcontrib><title>Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>The majority of Mycobacterium tuberculosis isolates resistant to isoniazid harbour a mutation in katG . Since these mutations cause a wide range of minimum inhibitory concentrations (MICs), largely below the serum level reached with higher dosing (15 mg/L upon 15–20 mg/kg), the drug might still remain partly active in presence of a katG mutation. We therefore investigated which genetic mutations predict the level of phenotypic isoniazid resistance in clinical M. tuberculosis isolates. To this end, the association between known and unknown isoniazid resistance-conferring mutations in whole genome sequences, and the isoniazid MICs of 176 isolates was examined. We found mostly moderate-level resistance characterized by a mode of 6.4 mg/L for the very common katG Ser315Thr mutation, and always very high MICs (≥19.2 mg/L) for the combination of katG Ser315Thr and inhA c-15t. Contrary to common belief, isolates harbouring inhA c-15t alone, partly also showed moderate-level resistance, particularly when combined with inhA Ser94Ala. No overt association between low-confidence or unknown mutations, except in katG , and isoniazid resistance (level) was found. Except for the rare katG deletion, line probe assay is thus not sufficiently accurate to predict the level of isoniazid resistance for a single mutation in katG or inhA .</description><subject>45/22</subject><subject>45/23</subject><subject>631/208/205</subject><subject>631/326/22/1434</subject><subject>631/326/2521</subject><subject>631/326/41/2530</subject><subject>631/326/421</subject><subject>Antitubercular Agents - pharmacology</subject><subject>Bacterial Proteins - genetics</subject><subject>Catalase - genetics</subject><subject>Drug Resistance, Bacterial</subject><subject>Genomes</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Isoniazid</subject><subject>Isoniazid - pharmacology</subject><subject>Microbial Sensitivity Tests</subject><subject>multidisciplinary</subject><subject>Mutation</subject><subject>Mycobacterium tuberculosis</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Mycobacterium tuberculosis - genetics</subject><subject>Mycobacterium tuberculosis - isolation &amp; purification</subject><subject>Oxidoreductases - genetics</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Tuberculosis</subject><subject>Tuberculosis - microbiology</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kcFuFSEUhidGY5vaF3BhSNy4GQUGZmBjYpqqTWrc6JoAc7iXhoErzDS97n1vmd7aVheyOQQ-Pjj8TfOS4LcEd-JdYYRL0WIiWkq6QbQ3T5pjihlvaUfp00fzo-a0lCtcB6eSEfm8OaqVy76Xx82vi5Ki1z_9iDIUX2YdLaAA1xAKSg592dtktJ0h-2VC82Ig2yWkSiKrIwo6byDskQG0yzD6Co7I7NHWb7atTdH5EVbhg_t2FXL2cYOmZdazT7G8aJ45HQqc3tWT5vvH829nn9vLr58uzj5ctpYTMrfADWOsgw6I7LElEjOBjbPS9INx2nLXD73hzGHAoxNMEG5HgoV0o2WAh-6keX_w7hYzwWghzlkHtct-0nmvkvbq753ot2qTrhUXRHC6Ct7cCXL6sUCZ1eSLhRB0hLQURTEeCOkHIiv6-h_0Ki051vZWihEiaE8rRQ-UzamUDO7-MQSrNWh1CFrVoNVt0OqmHnr1uI37I39irUB3AMpu_WjID3f_R_sbz824mQ</recordid><startdate>20180219</startdate><enddate>20180219</enddate><creator>Lempens, Pauline</creator><creator>Meehan, Conor J.</creator><creator>Vandelannoote, Koen</creator><creator>Fissette, Kristina</creator><creator>de Rijk, Pim</creator><creator>Van Deun, Armand</creator><creator>Rigouts, Leen</creator><creator>de Jong, Bouke C.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180219</creationdate><title>Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations</title><author>Lempens, Pauline ; Meehan, Conor J. ; Vandelannoote, Koen ; Fissette, Kristina ; de Rijk, Pim ; Van Deun, Armand ; Rigouts, Leen ; de Jong, Bouke C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-e5b4443e3e1960c190480bfc9b67bfac5f676b54f0e0df84815cd1089fdc4e073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>45/22</topic><topic>45/23</topic><topic>631/208/205</topic><topic>631/326/22/1434</topic><topic>631/326/2521</topic><topic>631/326/41/2530</topic><topic>631/326/421</topic><topic>Antitubercular Agents - pharmacology</topic><topic>Bacterial Proteins - genetics</topic><topic>Catalase - genetics</topic><topic>Drug Resistance, Bacterial</topic><topic>Genomes</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Isoniazid</topic><topic>Isoniazid - pharmacology</topic><topic>Microbial Sensitivity Tests</topic><topic>multidisciplinary</topic><topic>Mutation</topic><topic>Mycobacterium tuberculosis</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Mycobacterium tuberculosis - genetics</topic><topic>Mycobacterium tuberculosis - isolation &amp; purification</topic><topic>Oxidoreductases - genetics</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Tuberculosis</topic><topic>Tuberculosis - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lempens, Pauline</creatorcontrib><creatorcontrib>Meehan, Conor J.</creatorcontrib><creatorcontrib>Vandelannoote, Koen</creatorcontrib><creatorcontrib>Fissette, Kristina</creatorcontrib><creatorcontrib>de Rijk, Pim</creatorcontrib><creatorcontrib>Van Deun, Armand</creatorcontrib><creatorcontrib>Rigouts, Leen</creatorcontrib><creatorcontrib>de Jong, Bouke C.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lempens, Pauline</au><au>Meehan, Conor J.</au><au>Vandelannoote, Koen</au><au>Fissette, Kristina</au><au>de Rijk, Pim</au><au>Van Deun, Armand</au><au>Rigouts, Leen</au><au>de Jong, Bouke C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2018-02-19</date><risdate>2018</risdate><volume>8</volume><issue>1</issue><spage>3246</spage><epage>9</epage><pages>3246-9</pages><artnum>3246</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>The majority of Mycobacterium tuberculosis isolates resistant to isoniazid harbour a mutation in katG . Since these mutations cause a wide range of minimum inhibitory concentrations (MICs), largely below the serum level reached with higher dosing (15 mg/L upon 15–20 mg/kg), the drug might still remain partly active in presence of a katG mutation. We therefore investigated which genetic mutations predict the level of phenotypic isoniazid resistance in clinical M. tuberculosis isolates. To this end, the association between known and unknown isoniazid resistance-conferring mutations in whole genome sequences, and the isoniazid MICs of 176 isolates was examined. We found mostly moderate-level resistance characterized by a mode of 6.4 mg/L for the very common katG Ser315Thr mutation, and always very high MICs (≥19.2 mg/L) for the combination of katG Ser315Thr and inhA c-15t. Contrary to common belief, isolates harbouring inhA c-15t alone, partly also showed moderate-level resistance, particularly when combined with inhA Ser94Ala. No overt association between low-confidence or unknown mutations, except in katG , and isoniazid resistance (level) was found. Except for the rare katG deletion, line probe assay is thus not sufficiently accurate to predict the level of isoniazid resistance for a single mutation in katG or inhA .</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>29459669</pmid><doi>10.1038/s41598-018-21378-x</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2045-2322
ispartof Scientific reports, 2018-02, Vol.8 (1), p.3246-9, Article 3246
issn 2045-2322
2045-2322
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5818527
source MEDLINE; DOAJ Directory of Open Access Journals; Springer Nature OA Free Journals; Nature Free; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry
subjects 45/22
45/23
631/208/205
631/326/22/1434
631/326/2521
631/326/41/2530
631/326/421
Antitubercular Agents - pharmacology
Bacterial Proteins - genetics
Catalase - genetics
Drug Resistance, Bacterial
Genomes
Humanities and Social Sciences
Humans
Isoniazid
Isoniazid - pharmacology
Microbial Sensitivity Tests
multidisciplinary
Mutation
Mycobacterium tuberculosis
Mycobacterium tuberculosis - drug effects
Mycobacterium tuberculosis - genetics
Mycobacterium tuberculosis - isolation & purification
Oxidoreductases - genetics
Science
Science (multidisciplinary)
Tuberculosis
Tuberculosis - microbiology
title Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T14%3A17%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Isoniazid%20resistance%20levels%20of%20Mycobacterium%20tuberculosis%20can%20largely%20be%20predicted%20by%20high-confidence%20resistance-conferring%20mutations&rft.jtitle=Scientific%20reports&rft.au=Lempens,%20Pauline&rft.date=2018-02-19&rft.volume=8&rft.issue=1&rft.spage=3246&rft.epage=9&rft.pages=3246-9&rft.artnum=3246&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-018-21378-x&rft_dat=%3Cproquest_pubme%3E2004118262%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2004118262&rft_id=info:pmid/29459669&rfr_iscdi=true